These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25172241)

  • 41. Intravenous immunoglobulin use for neurologic diseases.
    Koski CL; Patterson JV
    J Infus Nurs; 2006; 29(3 Suppl):S21-8. PubMed ID: 16878852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis.
    Lazzaro C; Lopiano L; Cocito D
    Neurol Sci; 2014 Jul; 35(7):1023-34. PubMed ID: 24469345
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis.
    Racosta JM; Sposato LA; Kimpinski K
    Muscle Nerve; 2017 Jun; 55(6):802-809. PubMed ID: 27649063
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose.
    Berger M
    Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):532-8. PubMed ID: 21971330
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of autoimmune neuromuscular diseases with high-dose intravenous immune globulin.
    Soueidan SA; Dalakas MC
    Pediatr Res; 1993 Jan; 33(1 Suppl):S95-100. PubMed ID: 8433882
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravenous IgG (IVIG) and subcutaneous IgG (SCIG) preparations have comparable inhibitory effect on T cell activation, which is not dependent on IgG sialylation, monocytes or B cells.
    Issekutz AC; Rowter D; Miescher S; Käsermann F
    Clin Immunol; 2015 Oct; 160(2):123-32. PubMed ID: 25982320
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differentiating characteristics and evaluating intravenous and subcutaneous immunoglobulin.
    Ness S
    Am J Manag Care; 2019 Jun; 25(6 Suppl):S98-S104. PubMed ID: 31318515
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop.
    Adrichem ME; Eftimov F; van Schaik IN
    J Peripher Nerv Syst; 2016 Sep; 21(3):121-7. PubMed ID: 27241239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravenous immunoglobulin in neurological disease: a specialist review.
    Wiles CM; Brown P; Chapel H; Guerrini R; Hughes RA; Martin TD; McCrone P; Newsom-Davis J; Palace J; Rees JH; Rose MR; Scolding N; Webster AD
    J Neurol Neurosurg Psychiatry; 2002 Apr; 72(4):440-8. PubMed ID: 11909900
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy.
    Markvardsen LH; Harbo T; Sindrup SH; Christiansen I; Andersen H; Jakobsen J;
    Eur J Neurol; 2014 Dec; 21(12):1465-70. PubMed ID: 25041191
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases.
    Haddad É; Barnes D; Kafal A
    Transfus Apher Sci; 2012 Jun; 46(3):315-21. PubMed ID: 22503304
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins.
    Ritter C; Bobylev I; Lehmann HC
    J Neuroinflammation; 2015 Aug; 12():148. PubMed ID: 26268846
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plasmacytosis is a common immune signature in patients with MMN and CIDP and responds to treatment with IVIg.
    Korporal-Kuhnke M; Haas J; Schwarz A; Jarius S; Wildemann B
    J Neuroimmunol; 2015 Jan; 278():60-8. PubMed ID: 25595253
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Maintenance treatment with subcutaneous immunoglobulins in the long-term management of anti-HMCGR myopathy.
    Zuppa A; De Michelis C; Meo G; Prada V; Gemelli C; Infantino M; Manfredi M; Pesce G; Tagliafico AS; Benedetti L; Fiorillo C; Schenone A; Quartuccio L; Grandis M
    Neuromuscul Disord; 2021 Feb; 31(2):134-138. PubMed ID: 33461845
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: A systematic review and meta-analysis.
    Goswami RP; Haldar SN; Chatterjee M; Vij P; van der Kooi AJ; Lim J; Raaphorst J; Bhadu D; Gelardi C; Danieli MG; Kumar U
    Autoimmun Rev; 2022 Feb; 21(2):102997. PubMed ID: 34800685
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New Frontiers in Subcutaneous Immunoglobulin Treatment.
    Jolles S; Stein MR; Longhurst HJ; Borte M; Ritchie B; Sturzenegger MH; Berger M
    Biol Ther; 2011; 1(1):3. PubMed ID: 24392293
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chronic immunoglobulin maintenance therapy in myasthenia gravis.
    Alcantara M; Sarpong E; Barnett C; Katzberg H; Bril V
    Eur J Neurol; 2021 Feb; 28(2):639-646. PubMed ID: 32964565
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current treatments of chronic immune-mediated demyelinating polyneuropathies.
    Brannagan TH
    Muscle Nerve; 2009 May; 39(5):563-78. PubMed ID: 19301378
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition.
    Wada J; Shintani N; Kikutani K; Nakae T; Yamauchi T; Takechi K
    Clin Exp Immunol; 2001 May; 124(2):282-9. PubMed ID: 11422206
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency.
    Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA
    Vox Sang; 2019 Apr; 114(3):237-246. PubMed ID: 30883804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.